疫苗龙头定增刚终止，急赴港“补血”

Core Viewpoint - Oulin Biotech (688319) has submitted an application for overseas public offering of H-shares on the Hong Kong Stock Exchange, following a significant stock price increase of over 140% this year, despite previously terminating a 175 million yuan private placement plan [1][3]. Financial Performance - In 2022, Oulin Biotech experienced a 75.38% decline in net profit, with 2023 revenue at 496 million yuan, down 9.38% year-on-year, and a net profit of 17.56 million yuan, a decrease of 33.94% [4]. - The company is projected to recover in 2024, with expected revenue of 589 million yuan, an 18.69% increase, and a net profit of 20.76 million yuan, up 18.24% [6]. - By Q3 2025, revenue reached 507 million yuan, a 31.1% increase, and net profit surged to 47.48 million yuan, a 1079.4% increase [6]. Accounts Receivable - As of the end of 2024, accounts receivable stood at 566 million yuan, representing 62.37% of current assets, indicating a significant portion of revenue is tied up in receivables [6]. - By Q3 2025, accounts receivable further increased to 665 million yuan, a 25.84% rise year-on-year, with an average collection period of 385 days [7]. Market Position - Oulin Biotech holds over 80% market share in its main product, the adsorbed tetanus vaccine, which has consistently contributed a significant portion of the company's revenue [8]. - The adsorbed tetanus vaccine accounted for 80.1% of revenue in 2022, increasing to 87.9% in the first half of 2025, with a gross margin around 95% [8][9]. Research and Development Expenses - R&D expenses from 2022 to the first half of 2025 were approximately 122 million yuan, 114.7 million yuan, 134.2 million yuan, and 58.8 million yuan, respectively, constituting around 22.3% to 19.3% of total revenue [10]. - Sales and distribution expenses exceeded 50% of revenue in 2024, indicating high operational costs [10]. Financial Health - As of Q3 2025, total liabilities were 977 million yuan, with a debt-to-asset ratio of 50.21%, and cash reserves of 170 million yuan, suggesting a tight financial situation [11].